<DOC>
	<DOCNO>NCT01898585</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter study assess safety efficacy Zelboraf ( vemurafenib ) patient Braf V600 mutation positive metastatic melanoma . Patients receive Zelboraf 960 mg twice day progressive disease , unacceptable toxicity , consent withdrawal , death , reason deem treat physician study termination .</brief_summary>
	<brief_title>An Open-Label Study Zelboraf ( Vemurafenib ) Patients With Braf V600 Mutation Positive Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adults patient &gt; = 18 year age Patients histologically confirm metastatic melanoma ( surgically incurable unresectable stage IIIC stage IV ; AJCC ) document BRAF V600 mutation determine cobasÂ® BRAF V600 Mutation Test prior administration vemurafenib . Unresectable stage IIIC disease must confirmation surgical oncologist Patients either measurable nonmeasurable disease ( RECIST Version 1.1 ) Patients may may receive prior systemic therapy metastatic melanoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Patients must recover side effect recent systemic local treatment metastatic melanoma Adequate hematological , renal , liver function Negative serum pregnancy test screen Fertile men woman must use effective form contraception study least 6 month completion study Evidence symptomatic CNS lesion determine investigator , use steroid antiseizure medication treatment brain metastasis prior first administration vemurafenib Patients previous malignancy ( melanoma ) within past 2 year except patient treat control basal squamous cell carcinoma ( SCC ) skin carcinoma insitu cervix . Concurrent administration anticancer therapy ( e.g . chemotherapy , target therapy , experimental drug , etc . ) administer study Known hypersensitivity vemurafenib another BRAF inhibitor Pregnant lactate woman Refractory nausea vomiting , malabsorption , external biliary shunt , significant bowel resection would preclude adequate absorption . Any follow within 6 month prior first vemurafenib administration : myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischaemic attack , pulmonary embolism , hypertension adequately control current medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>